C. R. Bard, Inc. Earnings Cheat Sheet: Increasing Costs Tighten Margins
S&P 500 (NYSE:SPY) component C. R. Bard, Inc. (NYSE:BCR) reported its results for the second quarter. C.R. Bard, Inc. designs, manufactures and sells diagnostic, medical, surgical and patient care devices.
C. R. Bard Earnings Cheat Sheet for the Second Quarter
Results: Swung to a loss of $47.8 million (55 cents per diluted share) in the quarter. C. R. Bard, Inc. had a net income of $124.6 million or $1.29 per share in the year earlier quarter.
Revenue: Rose 7.6% to $725 million from the year earlier quarter.
Actual vs. Wall St. Expectations: BCR reported adjusted net income of $1.57 per share. By that measure, the company fell in line with the mean estimate of $1.57 per share. Analysts were expecting revenue of $728.9 million.
Quoting Management: Timothy M. Ring, chairman and chief executive officer, commented, “The strategic investments we have made over the past couple of years have produced our strongest international sales quarter in quite some time, helping us to meet our adjusted EPS commitment despite a challenging sales period in the United States. We remain focused on the long term and will continue to pursue growth through new product development, geographic expansion and business development.”
Revenue has risen the past four quarters. Revenue increased 7.6% to $700.3 million in the first quarter. The figure rose 5.9% in the fourth quarter of the last fiscal year from the year earlier and climbed 6.5% in the third quarter of the last fiscal year from the year-ago quarter.
The company fell in line with estimates last quarter after topping expectations in the previous two quarters. In the first quarter, it topped the mark by 5 cents, and in the fourth quarter of the last fiscal year, it was ahead by 6 cents.
BCR’s loss in the latest quarter follows profits in the previous three quarters. The company reported a profit of $131.9 million in the first quarter, a profit of $136.2 million in the fourth quarter of the last fiscal year and $127.5 million in the third of the last fiscal year.
Competitors to Watch: Teleflex Incorporated (NYSE:TFX), Covidien plc (NYSE:COV), Boston Scientific Corp. (NYSE:BSX), Merit Medical Systems, Inc. (NASDAQ:MMSI), AngioDynamics, Inc. (NASDAQ:ANGO), Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI), Theragenics Corporation (NYSE:TGX), Rochester Medical Corp. (NASDAQ:ROCM), CONMED Corporation (NASDAQ:CNMD), and Becton, Dickinson and Co. (NYSE:BDX).
(Source: Xignite Financials)